|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:AGAP2-RAB21 (FusionGDB2 ID:2811) |
Fusion Gene Summary for AGAP2-RAB21 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: AGAP2-RAB21 | Fusion gene ID: 2811 | Hgene | Tgene | Gene symbol | AGAP2 | RAB21 | Gene ID | 116986 | 23011 |
| Gene name | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | RAB21, member RAS oncogene family | |
| Synonyms | CENTG1|GGAP2|PIKE | - | |
| Cytomap | 12q14.1 | 12q21.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2Arf GAP with GTP-binding protein-like, ANK repeat and PH domains 2GTP-binding and GTPase activating protein 2centaurin, gamma 1cnt-g1phosphatidylinositol 3-kinase enhancerphosphoinosi | ras-related protein Rab-21GTP-binding protein RAB21 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q99490 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000257897, ENST00000547588, | ENST00000261263, | |
| Fusion gene scores | * DoF score | 8 X 7 X 5=280 | 6 X 6 X 4=144 |
| # samples | 8 | 7 | |
| ** MAII score | log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/144*10)=-1.04064198449735 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: AGAP2 [Title/Abstract] AND RAB21 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | AGAP2(58123422)-RAB21(72179311), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | AGAP2 | GO:0016197 | endosomal transport | 12388557 |
| Hgene | AGAP2 | GO:0030036 | actin cytoskeleton organization | 12388557 |
| Hgene | AGAP2 | GO:0042177 | negative regulation of protein catabolic process | 18374643 |
| Hgene | AGAP2 | GO:0045860 | positive regulation of protein kinase activity | 14761976 |
| Tgene | RAB21 | GO:0008089 | anterograde axonal transport | 22705394 |
| Tgene | RAB21 | GO:0017157 | regulation of exocytosis | 22705394 |
| Fusion gene breakpoints across AGAP2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across RAB21 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | SARC | TCGA-3B-A9HS-01A | AGAP2 | chr12 | 58123422 | - | RAB21 | chr12 | 72179311 | + |
Top |
Fusion Gene ORF analysis for AGAP2-RAB21 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000257897 | ENST00000261263 | AGAP2 | chr12 | 58123422 | - | RAB21 | chr12 | 72179311 | + |
| In-frame | ENST00000547588 | ENST00000261263 | AGAP2 | chr12 | 58123422 | - | RAB21 | chr12 | 72179311 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000257897 | AGAP2 | chr12 | 58123422 | - | ENST00000261263 | RAB21 | chr12 | 72179311 | + | 7024 | 1635 | 77 | 1777 | 566 |
| ENST00000547588 | AGAP2 | chr12 | 58123422 | - | ENST00000261263 | RAB21 | chr12 | 72179311 | + | 7946 | 2557 | 0 | 2699 | 899 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000257897 | ENST00000261263 | AGAP2 | chr12 | 58123422 | - | RAB21 | chr12 | 72179311 | + | 0.00039198 | 0.9996081 |
| ENST00000547588 | ENST00000261263 | AGAP2 | chr12 | 58123422 | - | RAB21 | chr12 | 72179311 | + | 0.000553429 | 0.9994466 |
Top |
Fusion Genomic Features for AGAP2-RAB21 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| AGAP2 | chr12 | 58123421 | - | RAB21 | chr12 | 72179310 | + | 0.020515032 | 0.979485 |
| AGAP2 | chr12 | 58123421 | - | RAB21 | chr12 | 72179310 | + | 0.020515032 | 0.979485 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for AGAP2-RAB21 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:58123422/chr12:72179311) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| AGAP2 | . |
| FUNCTION: GTPase-activating protein (GAP) for ARF1 and ARF5, which also shows strong GTPase activity. Isoform 1 participates in the prevention of neuronal apoptosis by enhancing PI3 kinase activity. It aids the coupling of metabotropic glutamate receptor 1 (GRM1) to cytoplasmic PI3 kinase by interacting with Homer scaffolding proteins, and also seems to mediate anti-apoptotic effects of NGF by activating nuclear PI3 kinase. Isoform 2 does not stimulate PI3 kinase but may protect cells from apoptosis by stimulating Akt. It also regulates the adapter protein 1 (AP-1)-dependent trafficking of proteins in the endosomal system. It seems to be oncogenic. It is overexpressed in cancer cells, prevents apoptosis and promotes cancer cell invasion. {ECO:0000269|PubMed:12640130, ECO:0000269|PubMed:14761976, ECO:0000269|PubMed:15118108, ECO:0000269|PubMed:16079295}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 413_420 | 516 | 837.0 | Nucleotide binding | GTP |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 457_461 | 516 | 837.0 | Nucleotide binding | GTP |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 515_518 | 516 | 837.0 | Nucleotide binding | GTP |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 676_910 | 516 | 837.0 | Domain | PH |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 931_1051 | 516 | 837.0 | Domain | Arf-GAP |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 405_572 | 516 | 837.0 | Region | Note=G domain |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 1090_1119 | 516 | 837.0 | Repeat | Note=ANK 1 |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 1123_1152 | 516 | 837.0 | Repeat | Note=ANK 2 |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 946_969 | 516 | 837.0 | Zinc finger | C4-type |
| Tgene | RAB21 | chr12:58123422 | chr12:72179311 | ENST00000261263 | 5 | 7 | 48_56 | 178 | 226.0 | Motif | Effector region | |
| Tgene | RAB21 | chr12:58123422 | chr12:72179311 | ENST00000261263 | 5 | 7 | 132_135 | 178 | 226.0 | Nucleotide binding | Note=GTP | |
| Tgene | RAB21 | chr12:58123422 | chr12:72179311 | ENST00000261263 | 5 | 7 | 162_164 | 178 | 226.0 | Nucleotide binding | Note=GTP | |
| Tgene | RAB21 | chr12:58123422 | chr12:72179311 | ENST00000261263 | 5 | 7 | 26_34 | 178 | 226.0 | Nucleotide binding | Note=GTP | |
| Tgene | RAB21 | chr12:58123422 | chr12:72179311 | ENST00000261263 | 5 | 7 | 74_78 | 178 | 226.0 | Nucleotide binding | GTP |
Top |
Fusion Gene Sequence for AGAP2-RAB21 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >2811_2811_1_AGAP2-RAB21_AGAP2_chr12_58123422_ENST00000257897_RAB21_chr12_72179311_ENST00000261263_length(transcript)=7024nt_BP=1635nt GGGGCCTTCTGAGGTTTGGGGGCTGTAGGGCCATGGGCCTCAGGGCCAGAGGTGGTTGTTAGCCTGGCAAGACAGGTCTGGGCAACATGC ATGCCCAGAGGCAGTTCGTTGTAGCTGCAGTGAGAGCAGAAGTCAGACGACATGAGGTGGCCAAGCAGGCTCTAAACCGCCTCAGGAAGC TGGCAGAGAGGGTGGACGACCCCGAACTCCAGGACAGCATCCAGGCCTCATTGGACAGCATTCGAGAGGCTGTGATCAATAGCCAGGAAT GGACTTTGAGCCGCTCCATTCCTGAACTGCGCCTGGGTGTGCTGGGCGATGCCAGGAGTGGGAAGTCATCGCTCATCCACCGATTCCTGA CTGGCTCATACCAGGTGCTGGAGAAGACAGAGAGTGAGCAGTACAAGAAAGAAATGTTGGTGGATGGACAGACACATCTGGTGCTAATCC GAGAGGAAGCTGGGGCACCTGATGCCAAGTTCTCAGGCTGGGCAGATGCTGTGATCTTCGTCTTCAGCCTGGAGGATGAGAACAGTTTCC AGGCTGTGAGCCGTCTCCATGGGCAGCTGAGTTCCCTTCGCGGGGAGGGACGAGGAGGCCTGGCCTTGGCACTGGTGGGGACACAAGACA GGATCAGTGCTTCCTCCCCTCGGGTGGTGGGAGATGCTCGTGCCAGAGCTCTGTGCGCGGACATGAAACGCTGCAGCTACTATGAGACTT GTGCAACCTATGGGCTCAATGTGGATCGGGTCTTCCAGGAGGTGGCCCAGAAGGTGGTGACCTTGCGCAAGCAGCAACAGCTTCTGGCTG CCTGCAAGTCCCTGCCCAGCTCCCCAAGCCACTCAGCTGCATCCACTCCGGTAGCTGGCCAGGCTAGTAACGGGGGCCACACTAGCGACT ACTCTTCTTCCCTCCCGTCCTCACCGAATGTTGGTCACCGGGAGCTCCGAGCCGAGGCAGCTGCAGTGGCTGGATTGAGCACCCCAGGGT CCCTGCACCGGGCAGCCAAGCGCAGGACCAGCCTTTTTGCGAATCGTCGGGGTAGTGACTCCGAGAAACGAAGCTTGGATAGTCGGGGAG AGACAACAGGGAGTGGGCGAGCCATCCCCATCAAACAGAGCTTCCTACTAAAACGAAGTGGCAATTCCTTGAACAAAGAATGGAAGAAGA AATATGTAACCCTGTCCAGTAATGGCTTTCTACTCTACCACCCCAGTATTAACGATTACATCCACAGTACCCACGGCAAGGAGATGGACT TGCTGCGAACAACAGTCAAAGTCCCGGGCAAGCGGCCCCCGAGGGCCATCTCTGCCTTTGGCCCCTCAGCCAGCATTAACGGGCTCGTCA AGGACATGAGCACTGTCCAGATGGGTGAAGGCCTGGAAGCCACTACTCCCATGCCAAGCCCTAGCCCCAGCCCCAGTTCCCTGCAGCCAC CACCAGATCAGACATCCAAACACCTGCTGAAGCCAGACCGGAATTTGGCCCGAGCCCTCAGCACGGACTGTACCCCATCTGGAGACCTGA GCCCCCTGAGTCGGGAACCCCCTCCTTCTCCCATGGTGAAGAAGCAGAGGAGGAAAAAATTGACAACACCATCCAAGACTGAAGGCTCGG CTGGGCAGGCTGAAGGGATGATAGAAACAGCACAAGTGGATGAGAGAGCAAAAGGCAATGGCTCTAGTCAGCCGGGAACTGCAAGGCGAG GTGTACAGATTATTGATGATGAACCTCAAGCCCAGACCAGTGGTGGAGGGTGCTGTTCTTCTGGATAACTGTTCACGCCTAAGAAATTAA AAGACAGAACAAAACTGTGGATCATTGCCCTCAACATGAAGACTGCCATATTCCAAGTCACATTATTTTACCAATGGAATTATAGAATTA ACAGTATTTTAAATTACGTTTATAACACTGCAGAGACCTTAAGTGCTAAACTTAGTGGAGTTTGTGACCAGAGAATTGGCATTTTCTACA AATGTTTTTTTTTGTTTTTTTTTTGTTTTTTTTTGTTTTTTTTTGAGACGGAGTCTCGCTCTGTCACCCAGGCTGGAGTGCACTGGCTTG ATCTCGGCTCACTGCAAGCTCCACCTCCCAGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTATAGGCGCCCACCAC GACGCCCGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCAGGTTAGCCAGGATGGTCTCGATCTCCTGACCTTGTGATCCGC CCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGTGCCCGGCCTACAAATGTTAACAAAGCAATTACCAATGGCCTTT TTACATATTTTTTCTTTAATGAGGAATAATATGCATGTAGAAAAGACCTACTTAAAGTCTTCATTTATATTCTTTCAAATCAAATCTTTA TTTAATAACTTATATATGTTGTTGGAATGGTTACATTTTTGCAGCCCTTTGTATTTTGTGGTAGTTGAAATTGTATCACTTCTAAACAGC AAACTGTTTTTGTTTTTAATTAGCAGATATCTGAAGTACTATTTTTGCAGGGTTTGCACAGGCCCGTAACTGTCTACTACTTTGATATAA TCTGTATACATCCTGTATGCTGAGCTGGTAAAATACATTGTAAATTACATATTAAATATTTTATCTGCTTTTACAAGCGCAAGGTGCAAA AATATATACAATAGTCTCATTGATGACTGTAAAGTGAATTAACATTTGGTGATTATGCCTAGCTTTTTTGACTAATATAAAGATCATAGC TCCCCTTCACTTCTGTCTTAACTTGAACATGGCGTGTTTAAATTTTCATACATACTTTACTTGAATTATTGCTGTTGTCACATATTTTTG CCTCTGTGAGTTCATCTGATGATTGAGCAGTAGCATTTGCCTTTTGGGTTTTTTGTTTGTTATTATAGAAGAGATGACTTCTGCTGATTT TGCTTTAGAATGGTTACCTTAGAAGAATTTGGGTGGCTCATGTTGAATTTCACTTCTGCAATAGCTTTCATTTTCTCATAGGCTTTATAA GAGATGGGTTCAGTGGTATGAGCAGAGGAAGAGATCCCAGATAGTAGCCAGTTAACCAAGACTCATTCATATAGCACGTAGTTTATGTTC CTGAGGCAGCACTTTTAGATCCTTTGTGAGCAAGTTCTATTTGTTCATTGCTTGCCAGAGATGAACACAGAATGTTCTGTTTCATTTTAC AAGAACTATCCTGAGTTTCTGTGGATGGAAACATTACATGTAATGCAGATATAGTGAACACTGGAAAGATTTATTAAAGAATTATATTTG TGTATACTTTATAAATTAGTCCCTCATTAGATTTTTTTTTCTTAAGCATAAGACTGAACTTAAATGTGTTAATTTTAGTAGAATCAGGCA CTGCTCGCAGAAGGAACACAGATTGTAGAGATTAACATAAATTGTTCTTGTTCTAATATATATATTTTTTCATTTCTGTCGTGCTTGGAA AACTAGTAAATATTATGTCTAAGATAAAATGGAATGGCCCCTGGATTTACTTCTTATAAGAAGCAGTAGTATGTAATAAAGCTATTAGCA TGAGCAATTAAGAGGCTATAAAGAGATTATAGTTACAAAAGAAATACTGCCATATTTTTAAGTTAATAACTTAAACCTTCTCAAATGGGT TAAAAGTTGAATGAATTGACACCCTGATGTTATGATGTTGGAATTTTAACTTAAACTGGGAGGCATTCTGTGAGCCTTCACTTTACCTTC TTTAATTATTGTCCTTGCTAAACTCAACACAGACTTTTCTGTTATGTGTTTTTGAGGAAGTTGGGGTGGGAAGAGTCAGGGAGATAAGCT AAAATTGTCTTCTTTTATGGGGTAATTGTACTCTGTAGTCTCTTGGTTTCCTGTGAAGTTAGTATTTATGTGGGGGTGGGGGAAGGTAGC AAGAATCATGGGTATCACGGTACTTTGTTTTTGACCTCCTGGCTCTTTCAGACAGAGTGAAGAAAGCTTTTCCATTCTTACTGTTGTAGA AGTAGATAGGAAATAAGCTTTTCTCATTACAGTGAAATATGTTTTAAAAACTAGAGTAGCTGGGCACAGAGGCATGCATTTGTAGGGCCA GCTACTTGGGAGAGTGAGGCAGGAGGATCACTTGAGGCCAGGATTTCAAATCCAGCCTAGGTAACACTGAGACCTCCATCTCGTAAAAGG CACAAAAACTAGTTAGAGATGAAATTGAGCTTTATTTTAAAAAAACGTTCTAAAGCCTGATAATTGGAGAGCTATACTTCAGCTTTTCAT CCTACTTTAATGAAACAGCTAGATAGGAACCTCTGCTCCAGAATTGCCAGATAATTATTGGTGGGTCATAACTATTCTTCATATTTTTTT TTTCTTTTTTCTCCTTTGGTTTCTGTGTTATCTTTCTTAACCTCACGTATTTCTTTATCCTTTTTAGTGGGGGCCTGTAATTGAGGCTAA TTCAATAGCAACAATAGACAACATGATATGGCTGCTGTCACTTTGAAACCCAAAAGGTCTTTGGGTAGGAATAGAGTAATGAAAGAGGAC CAGTCAACTTCAGTATATATACAAAGGAAAGACAAAGAGATGATAAACCAAGGCTGAGGAAATTTTTCTGATGCTTTCTTCATTTCTCTA ATATACCTTTTGCATTCTTTTTCTGATAATTGTGCTATTAGGCAGAAGACACAAGTTACCACGTTGTGTATTAAAAGCAGTAGGTAGGTT GTGCCAGTATTTTTTCAGCCAGTAAGCATATACAGTTAACTTATATAATTAAAAATTGGTTTAAGATAGTGATTAAAAATACCTGAATAT TATGTTAAAAGTATACAATCATTGTTTCTGTAATGATGATGGGTATTCTGCTTCTTGTTTTTCATTGTAATTACAGGGGAAGATTGTTTT TGAAAATGTATATTGCCATGCTTTTGGGGTAAGCAGTAATGTGAAAAGAAAAAAGCATTATGTTATTGTATGAAATATAAGTGTTCAGAT TTGTTTTGTCTGGGGTGTTGCCTAAGAATACCCTAAAGCTATGGCTGTTACTGCATTGAAATCTTTTTTTTTTTTAATAGTAGCCATATG TTATTAGTGGAGTACTTTATATTTGACATTAAAGTGAAGAAGAAGAGTAGTACTTCACTTTTAGGTTTTTAGTAGTGAAAGATAAAATTG GAAAAATAGGGAAAGAGCATAGGGAGGAATAGAATGGAAGTCAAGTAAATAAAAAACTACAACCTGACAGTTTTTTAAATCACTTTGAAA AGTACATTACTTTTATCAAAGAGTTTCTAATTAAGGCAAACTATGCATTATGCCAAATATTAAGAACATTTTAAAAATGGATTGTGATAC TGTTTATTTCTTTAATTATATAATTTGCAATTTTCTGTATTATAAGTGCTACCAGGATTCTAGATAGTTGATCTTACATATTCAGATAGT ATAGTTTACTCTTATAATTACCCGTTACGTTATCTCTAAAAGTAGTTTGATCTGTGCCTTTAACTTTTAGAATTCATCTTTTGACTTGTT TGCCACTGTAGAGTTTTCAGTTTTCTCTGTAGATTCAGTGTGACAAAGAGGGAATACATAATTTGTGACCATTTAAGATGCTGATATTTT CTGGAAAAGGATATAGATAGTAGTAGTGACCCGCAGGAGCCTCACAATAATGTCTAAAGATATAAACTGAGTAGATCCCTAAGTACTCTT CTCTAAATTATAAAATGCATTACCTAGGCTTTAATAGTTAAAAGCTGGAATTTATTGAACCGCATCTACTTGATTTCATAATATGCATTG ATTTTAGTATGTTGCTGTTCTGTTATCTGTAATCAACTATAACAGAGTAATATATTTGGTGTTCTGGACCAAAATTCGTGCTACACATAT GTCTGATGGCCTTTACCTTTTCAAGAAAACAGTTGCAATTTTGAGCAAAATTTTCCTAGTTGTAATATTTTAATAGTGTTATGTATTGGA AAAAATTTAGAAATACTCCTAAGAGTTTTCAATTTCAAGCAGAAATGCTTCTCTTCTAAATAAATACCACTTAATTGATAGACCTTTAGC AGTTCTTGTGCTATCTAGGATTTATACATTTTTGCTTTTCTGGAAAACTGCTTTGGCGCATTAACCTTTCTACTGCAACATTTTCTCTTC AGTAGATATATGAGTAAACATGATGAGTTAATGTTACACAGCATACCCAGTTAGGTCTCTTATTCTTAAAGCATCTTTCTTTAGAAGTCT GCACATATTTTCAAATGCATCATATTAAAGGCACAAGTCAAGAGGAGGTGGAGTTGCCTACTTCAGTGGCCTTTATTCCCACTATACCAG TTCTCAGTCTTGATTTTGATACTTTCTGGCAACTGTATCATCTCTTCACTATCACGTATTTTAAGAAAAAGCTAAGGTGATTTCTTTACA TTTGAACATGTGTAGATCAATGAGAGAATGGTGAGGGATAGCAAGGATAAAGTATAATGTTGAAAAGTAGAAAGAAGTGGTATCTGCTAA ACTCTAGCTTTAGTAGCAAGCTATTTTAAGGAAATCATTGTATGTGGTACTTCCTAGAAATATGAAAGTTCCTCATTTTGTATTTAATTA TGTAAGAAAATGTTCTAGGAAAAGAATAAAAAACATATATTGTCAAAGTGCCCTTTGGTAGTGCTCCCAAATGGTAGTAACTATTGGTCT CTAGTATATACTCCTCAAATATCTTTTTGCTATGTATTAATATATCTATATGTTTACATATAGAAATACATAGTGTTGTGGGTTTTAAAT TTTCACATAAATTGTGTCTTACCCATGTGTTTTGCCATTTGCCTTTTCTCTTGCCAACGTGTCTAGGAGCTCTTTGGTAAATACAGACTT TTTCATTTTATTTCCTCCCACATTTCTATGGATGTGTCTTGCCTTTTTCTTTTTTTTTTCTTTCTTTTTTTCTTTTTTAAAATAGCCTCT >2811_2811_1_AGAP2-RAB21_AGAP2_chr12_58123422_ENST00000257897_RAB21_chr12_72179311_ENST00000261263_length(amino acids)=566AA_BP=519 MGNMHAQRQFVVAAVRAEVRRHEVAKQALNRLRKLAERVDDPELQDSIQASLDSIREAVINSQEWTLSRSIPELRLGVLGDARSGKSSLI HRFLTGSYQVLEKTESEQYKKEMLVDGQTHLVLIREEAGAPDAKFSGWADAVIFVFSLEDENSFQAVSRLHGQLSSLRGEGRGGLALALV GTQDRISASSPRVVGDARARALCADMKRCSYYETCATYGLNVDRVFQEVAQKVVTLRKQQQLLAACKSLPSSPSHSAASTPVAGQASNGG HTSDYSSSLPSSPNVGHRELRAEAAAVAGLSTPGSLHRAAKRRTSLFANRRGSDSEKRSLDSRGETTGSGRAIPIKQSFLLKRSGNSLNK EWKKKYVTLSSNGFLLYHPSINDYIHSTHGKEMDLLRTTVKVPGKRPPRAISAFGPSASINGLVKDMSTVQMGEGLEATTPMPSPSPSPS SLQPPPDQTSKHLLKPDRNLARALSTDCTPSGDLSPLSREPPPSPMVKKQRRKKLTTPSKTEGSAGQAEGMIETAQVDERAKGNGSSQPG -------------------------------------------------------------- >2811_2811_2_AGAP2-RAB21_AGAP2_chr12_58123422_ENST00000547588_RAB21_chr12_72179311_ENST00000261263_length(transcript)=7946nt_BP=2557nt ATGAGCCGGGGCGCGGGCGCGCTTCAGCGCCGGACAACGACCTACCTCATCTCGCTGACCCTGGTTAAGCTCGAGTCGGTGCCTCCGCCG CCGCCTTCTCCGTCTGCGGCCGCGGCCGGCGCCGCCGGTGCCAGAGGCTCCGAGACTGGGGATCCTGGCAGCCCCCGAGGCGCGGAGGAG CCGGGCAAGAAGCGGCACGAACGTCTCTTCCACCGGCAGGATGCGCTGTGGATCAGCACGAGCAGCGCGGGCACCGGGGGCGCGGAGCCC CCAGCCCTGTCCCCGGCTCCGGCCAGTCCGGCCCGCCCAGTCTCCCCCGCTCCCGGCCGCCGCCTCTCCCTCTGGGCCGTCCCTCCGGGA CCCCCGCTCTCCGGGGGACTGAGCCCCGACCCCAAGCCTGGGGGCGCCCCCACCTCCTCCCGGCGCCCCCTGCTCAGCAGCCCGAGCTGG GGCGGCCCGGAGCCCGAAGGCCGGGCGGGCGGCGGCATCCCTGGCTCATCCTCTCCGCACCCTGGCACCGGCAGCCGGAGGCTCAAGGTG GCGCCTCCTCCGCCGGCTCCCAAGCCTTGCAAGACCGTGACCACGAGTGGAGCCAAAGCCGGCGGGGGCAAGGGCGCGGGTAGCCGCCTG TCATGGCCCGAAAGCGAGGGCAAGCCCAGGGTCAAGGGGTCAAAGAGCAGCGCCGGGACTGGAGCTTCGGTCTCTGCCGCCGCCACCGCC GCCGCCGCCGGGGGAGGGGGCTCTACAGCTTCGACCTCTGGTGGGGTCGGGGCTGGGGCTGGAGCCCGAGGGAAGTTGTCCCCTCGGAAA GGCAAGAGTAAGACCTTGGACAACAGTGACTTGCATCCGGGACCGCCTGCCGGCTCTCCTCCTCCGCTAACCCTCCCACCAACTCCGAGT CCAGCCACTGCTGTCACCGCTGCTTCCGCGCAGCCCCCCGGGCCTGCACCTCCAATCACTCTGGAGCCTCCAGCTCCGGGGCTGAAACGG GGCCGGGAGGGGGGCCGAGCATCCACTCGTGACCGCAAGATGCTCAAGTTTATCAGCGGCATCTTCACCAAGAGCACAGGAGGGCCTCCT GGCTCCGGGCCCCTTCCCGGACCCCCCAGCCTGTCTTCTGGCAGCGGGTCCAGGGAGCTGCTGGGCGCCGAGCTCCGCGCTTCCCCTAAG GCTGTGATCAATAGCCAGGAATGGACTTTGAGCCGCTCCATTCCTGAACTGCGCCTGGGTGTGCTGGGCGATGCCAGGAGTGGGAAGTCA TCGCTCATCCACCGATTCCTGACTGGCTCATACCAGGTGCTGGAGAAGACAGAGAGTGAGCAGTACAAGAAAGAAATGTTGGTGGATGGA CAGACACATCTGGTGCTAATCCGAGAGGAAGCTGGGGCACCTGATGCCAAGTTCTCAGGCTGGGCAGATGCTGTGATCTTCGTCTTCAGC CTGGAGGATGAGAACAGTTTCCAGGCTGTGAGCCGTCTCCATGGGCAGCTGAGTTCCCTTCGCGGGGAGGGACGAGGAGGCCTGGCCTTG GCACTGGTGGGGACACAAGACAGGATCAGTGCTTCCTCCCCTCGGGTGGTGGGAGATGCTCGTGCCAGAGCTCTGTGCGCGGACATGAAA CGCTGCAGCTACTATGAGACTTGTGCAACCTATGGGCTCAATGTGGATCGGGTCTTCCAGGAGGTGGCCCAGAAGGTGGTGACCTTGCGC AAGCAGCAACAGCTTCTGGCTGCCTGCAAGTCCCTGCCCAGCTCCCCAAGCCACTCAGCTGCATCCACTCCGGTAGCTGGCCAGGCTAGT AACGGGGGCCACACTAGCGACTACTCTTCTTCCCTCCCGTCCTCACCGAATGTTGGTCACCGGGAGCTCCGAGCCGAGGCAGCTGCAGTG GCTGGATTGAGCACCCCAGGGTCCCTGCACCGGGCAGCCAAGCGCAGGACCAGCCTTTTTGCGAATCGTCGGGGTAGTGACTCCGAGAAA CGAAGCTTGGATAGTCGGGGAGAGACAACAGGGAGTGGGCGAGCCATCCCCATCAAACAGAGCTTCCTACTAAAACGAAGTGGCAATTCC TTGAACAAAGAATGGAAGAAGAAATATGTAACCCTGTCCAGTAATGGCTTTCTACTCTACCACCCCAGTATTAACGATTACATCCACAGT ACCCACGGCAAGGAGATGGACTTGCTGCGAACAACAGTCAAAGTCCCGGGCAAGCGGCCCCCGAGGGCCATCTCTGCCTTTGGCCCCTCA GCCAGCATTAACGGGCTCGTCAAGGACATGAGCACTGTCCAGATGGGTGAAGGCCTGGAAGCCACTACTCCCATGCCAAGCCCTAGCCCC AGCCCCAGTTCCCTGCAGCCACCACCAGATCAGACATCCAAACACCTGCTGAAGCCAGACCGGAATTTGGCCCGAGCCCTCAGCACGGAC TGTACCCCATCTGGAGACCTGAGCCCCCTGAGTCGGGAACCCCCTCCTTCTCCCATGGTGAAGAAGCAGAGGAGGAAAAAATTGACAACA CCATCCAAGACTGAAGGCTCGGCTGGGCAGGCTGAAGGGATGATAGAAACAGCACAAGTGGATGAGAGAGCAAAAGGCAATGGCTCTAGT CAGCCGGGAACTGCAAGGCGAGGTGTACAGATTATTGATGATGAACCTCAAGCCCAGACCAGTGGTGGAGGGTGCTGTTCTTCTGGATAA CTGTTCACGCCTAAGAAATTAAAAGACAGAACAAAACTGTGGATCATTGCCCTCAACATGAAGACTGCCATATTCCAAGTCACATTATTT TACCAATGGAATTATAGAATTAACAGTATTTTAAATTACGTTTATAACACTGCAGAGACCTTAAGTGCTAAACTTAGTGGAGTTTGTGAC CAGAGAATTGGCATTTTCTACAAATGTTTTTTTTTGTTTTTTTTTTGTTTTTTTTTGTTTTTTTTTGAGACGGAGTCTCGCTCTGTCACC CAGGCTGGAGTGCACTGGCTTGATCTCGGCTCACTGCAAGCTCCACCTCCCAGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGC TGGGACTATAGGCGCCCACCACGACGCCCGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCAGGTTAGCCAGGATGGTCTCG ATCTCCTGACCTTGTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGTGCCCGGCCTACAAATGTTAAC AAAGCAATTACCAATGGCCTTTTTACATATTTTTTCTTTAATGAGGAATAATATGCATGTAGAAAAGACCTACTTAAAGTCTTCATTTAT ATTCTTTCAAATCAAATCTTTATTTAATAACTTATATATGTTGTTGGAATGGTTACATTTTTGCAGCCCTTTGTATTTTGTGGTAGTTGA AATTGTATCACTTCTAAACAGCAAACTGTTTTTGTTTTTAATTAGCAGATATCTGAAGTACTATTTTTGCAGGGTTTGCACAGGCCCGTA ACTGTCTACTACTTTGATATAATCTGTATACATCCTGTATGCTGAGCTGGTAAAATACATTGTAAATTACATATTAAATATTTTATCTGC TTTTACAAGCGCAAGGTGCAAAAATATATACAATAGTCTCATTGATGACTGTAAAGTGAATTAACATTTGGTGATTATGCCTAGCTTTTT TGACTAATATAAAGATCATAGCTCCCCTTCACTTCTGTCTTAACTTGAACATGGCGTGTTTAAATTTTCATACATACTTTACTTGAATTA TTGCTGTTGTCACATATTTTTGCCTCTGTGAGTTCATCTGATGATTGAGCAGTAGCATTTGCCTTTTGGGTTTTTTGTTTGTTATTATAG AAGAGATGACTTCTGCTGATTTTGCTTTAGAATGGTTACCTTAGAAGAATTTGGGTGGCTCATGTTGAATTTCACTTCTGCAATAGCTTT CATTTTCTCATAGGCTTTATAAGAGATGGGTTCAGTGGTATGAGCAGAGGAAGAGATCCCAGATAGTAGCCAGTTAACCAAGACTCATTC ATATAGCACGTAGTTTATGTTCCTGAGGCAGCACTTTTAGATCCTTTGTGAGCAAGTTCTATTTGTTCATTGCTTGCCAGAGATGAACAC AGAATGTTCTGTTTCATTTTACAAGAACTATCCTGAGTTTCTGTGGATGGAAACATTACATGTAATGCAGATATAGTGAACACTGGAAAG ATTTATTAAAGAATTATATTTGTGTATACTTTATAAATTAGTCCCTCATTAGATTTTTTTTTCTTAAGCATAAGACTGAACTTAAATGTG TTAATTTTAGTAGAATCAGGCACTGCTCGCAGAAGGAACACAGATTGTAGAGATTAACATAAATTGTTCTTGTTCTAATATATATATTTT TTCATTTCTGTCGTGCTTGGAAAACTAGTAAATATTATGTCTAAGATAAAATGGAATGGCCCCTGGATTTACTTCTTATAAGAAGCAGTA GTATGTAATAAAGCTATTAGCATGAGCAATTAAGAGGCTATAAAGAGATTATAGTTACAAAAGAAATACTGCCATATTTTTAAGTTAATA ACTTAAACCTTCTCAAATGGGTTAAAAGTTGAATGAATTGACACCCTGATGTTATGATGTTGGAATTTTAACTTAAACTGGGAGGCATTC TGTGAGCCTTCACTTTACCTTCTTTAATTATTGTCCTTGCTAAACTCAACACAGACTTTTCTGTTATGTGTTTTTGAGGAAGTTGGGGTG GGAAGAGTCAGGGAGATAAGCTAAAATTGTCTTCTTTTATGGGGTAATTGTACTCTGTAGTCTCTTGGTTTCCTGTGAAGTTAGTATTTA TGTGGGGGTGGGGGAAGGTAGCAAGAATCATGGGTATCACGGTACTTTGTTTTTGACCTCCTGGCTCTTTCAGACAGAGTGAAGAAAGCT TTTCCATTCTTACTGTTGTAGAAGTAGATAGGAAATAAGCTTTTCTCATTACAGTGAAATATGTTTTAAAAACTAGAGTAGCTGGGCACA GAGGCATGCATTTGTAGGGCCAGCTACTTGGGAGAGTGAGGCAGGAGGATCACTTGAGGCCAGGATTTCAAATCCAGCCTAGGTAACACT GAGACCTCCATCTCGTAAAAGGCACAAAAACTAGTTAGAGATGAAATTGAGCTTTATTTTAAAAAAACGTTCTAAAGCCTGATAATTGGA GAGCTATACTTCAGCTTTTCATCCTACTTTAATGAAACAGCTAGATAGGAACCTCTGCTCCAGAATTGCCAGATAATTATTGGTGGGTCA TAACTATTCTTCATATTTTTTTTTTCTTTTTTCTCCTTTGGTTTCTGTGTTATCTTTCTTAACCTCACGTATTTCTTTATCCTTTTTAGT GGGGGCCTGTAATTGAGGCTAATTCAATAGCAACAATAGACAACATGATATGGCTGCTGTCACTTTGAAACCCAAAAGGTCTTTGGGTAG GAATAGAGTAATGAAAGAGGACCAGTCAACTTCAGTATATATACAAAGGAAAGACAAAGAGATGATAAACCAAGGCTGAGGAAATTTTTC TGATGCTTTCTTCATTTCTCTAATATACCTTTTGCATTCTTTTTCTGATAATTGTGCTATTAGGCAGAAGACACAAGTTACCACGTTGTG TATTAAAAGCAGTAGGTAGGTTGTGCCAGTATTTTTTCAGCCAGTAAGCATATACAGTTAACTTATATAATTAAAAATTGGTTTAAGATA GTGATTAAAAATACCTGAATATTATGTTAAAAGTATACAATCATTGTTTCTGTAATGATGATGGGTATTCTGCTTCTTGTTTTTCATTGT AATTACAGGGGAAGATTGTTTTTGAAAATGTATATTGCCATGCTTTTGGGGTAAGCAGTAATGTGAAAAGAAAAAAGCATTATGTTATTG TATGAAATATAAGTGTTCAGATTTGTTTTGTCTGGGGTGTTGCCTAAGAATACCCTAAAGCTATGGCTGTTACTGCATTGAAATCTTTTT TTTTTTTAATAGTAGCCATATGTTATTAGTGGAGTACTTTATATTTGACATTAAAGTGAAGAAGAAGAGTAGTACTTCACTTTTAGGTTT TTAGTAGTGAAAGATAAAATTGGAAAAATAGGGAAAGAGCATAGGGAGGAATAGAATGGAAGTCAAGTAAATAAAAAACTACAACCTGAC AGTTTTTTAAATCACTTTGAAAAGTACATTACTTTTATCAAAGAGTTTCTAATTAAGGCAAACTATGCATTATGCCAAATATTAAGAACA TTTTAAAAATGGATTGTGATACTGTTTATTTCTTTAATTATATAATTTGCAATTTTCTGTATTATAAGTGCTACCAGGATTCTAGATAGT TGATCTTACATATTCAGATAGTATAGTTTACTCTTATAATTACCCGTTACGTTATCTCTAAAAGTAGTTTGATCTGTGCCTTTAACTTTT AGAATTCATCTTTTGACTTGTTTGCCACTGTAGAGTTTTCAGTTTTCTCTGTAGATTCAGTGTGACAAAGAGGGAATACATAATTTGTGA CCATTTAAGATGCTGATATTTTCTGGAAAAGGATATAGATAGTAGTAGTGACCCGCAGGAGCCTCACAATAATGTCTAAAGATATAAACT GAGTAGATCCCTAAGTACTCTTCTCTAAATTATAAAATGCATTACCTAGGCTTTAATAGTTAAAAGCTGGAATTTATTGAACCGCATCTA CTTGATTTCATAATATGCATTGATTTTAGTATGTTGCTGTTCTGTTATCTGTAATCAACTATAACAGAGTAATATATTTGGTGTTCTGGA CCAAAATTCGTGCTACACATATGTCTGATGGCCTTTACCTTTTCAAGAAAACAGTTGCAATTTTGAGCAAAATTTTCCTAGTTGTAATAT TTTAATAGTGTTATGTATTGGAAAAAATTTAGAAATACTCCTAAGAGTTTTCAATTTCAAGCAGAAATGCTTCTCTTCTAAATAAATACC ACTTAATTGATAGACCTTTAGCAGTTCTTGTGCTATCTAGGATTTATACATTTTTGCTTTTCTGGAAAACTGCTTTGGCGCATTAACCTT TCTACTGCAACATTTTCTCTTCAGTAGATATATGAGTAAACATGATGAGTTAATGTTACACAGCATACCCAGTTAGGTCTCTTATTCTTA AAGCATCTTTCTTTAGAAGTCTGCACATATTTTCAAATGCATCATATTAAAGGCACAAGTCAAGAGGAGGTGGAGTTGCCTACTTCAGTG GCCTTTATTCCCACTATACCAGTTCTCAGTCTTGATTTTGATACTTTCTGGCAACTGTATCATCTCTTCACTATCACGTATTTTAAGAAA AAGCTAAGGTGATTTCTTTACATTTGAACATGTGTAGATCAATGAGAGAATGGTGAGGGATAGCAAGGATAAAGTATAATGTTGAAAAGT AGAAAGAAGTGGTATCTGCTAAACTCTAGCTTTAGTAGCAAGCTATTTTAAGGAAATCATTGTATGTGGTACTTCCTAGAAATATGAAAG TTCCTCATTTTGTATTTAATTATGTAAGAAAATGTTCTAGGAAAAGAATAAAAAACATATATTGTCAAAGTGCCCTTTGGTAGTGCTCCC AAATGGTAGTAACTATTGGTCTCTAGTATATACTCCTCAAATATCTTTTTGCTATGTATTAATATATCTATATGTTTACATATAGAAATA CATAGTGTTGTGGGTTTTAAATTTTCACATAAATTGTGTCTTACCCATGTGTTTTGCCATTTGCCTTTTCTCTTGCCAACGTGTCTAGGA GCTCTTTGGTAAATACAGACTTTTTCATTTTATTTCCTCCCACATTTCTATGGATGTGTCTTGCCTTTTTCTTTTTTTTTTCTTTCTTTT >2811_2811_2_AGAP2-RAB21_AGAP2_chr12_58123422_ENST00000547588_RAB21_chr12_72179311_ENST00000261263_length(amino acids)=899AA_BP=852 MSRGAGALQRRTTTYLISLTLVKLESVPPPPPSPSAAAAGAAGARGSETGDPGSPRGAEEPGKKRHERLFHRQDALWISTSSAGTGGAEP PALSPAPASPARPVSPAPGRRLSLWAVPPGPPLSGGLSPDPKPGGAPTSSRRPLLSSPSWGGPEPEGRAGGGIPGSSSPHPGTGSRRLKV APPPPAPKPCKTVTTSGAKAGGGKGAGSRLSWPESEGKPRVKGSKSSAGTGASVSAAATAAAAGGGGSTASTSGGVGAGAGARGKLSPRK GKSKTLDNSDLHPGPPAGSPPPLTLPPTPSPATAVTAASAQPPGPAPPITLEPPAPGLKRGREGGRASTRDRKMLKFISGIFTKSTGGPP GSGPLPGPPSLSSGSGSRELLGAELRASPKAVINSQEWTLSRSIPELRLGVLGDARSGKSSLIHRFLTGSYQVLEKTESEQYKKEMLVDG QTHLVLIREEAGAPDAKFSGWADAVIFVFSLEDENSFQAVSRLHGQLSSLRGEGRGGLALALVGTQDRISASSPRVVGDARARALCADMK RCSYYETCATYGLNVDRVFQEVAQKVVTLRKQQQLLAACKSLPSSPSHSAASTPVAGQASNGGHTSDYSSSLPSSPNVGHRELRAEAAAV AGLSTPGSLHRAAKRRTSLFANRRGSDSEKRSLDSRGETTGSGRAIPIKQSFLLKRSGNSLNKEWKKKYVTLSSNGFLLYHPSINDYIHS THGKEMDLLRTTVKVPGKRPPRAISAFGPSASINGLVKDMSTVQMGEGLEATTPMPSPSPSPSSLQPPPDQTSKHLLKPDRNLARALSTD -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for AGAP2-RAB21 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 1_23 | 516.3333333333334 | 837.0 | EPB41L1 |
| Hgene | AGAP2 | chr12:58123422 | chr12:72179311 | ENST00000257897 | - | 13 | 18 | 267_390 | 516.3333333333334 | 837.0 | PLCG1 |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for AGAP2-RAB21 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for AGAP2-RAB21 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies